Elizaveta Panchenko

Dr. Elizaveta Panchenko

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
EPElizaveta Panchenko
Elizaveta Panchenko
TBTatyana Balakhonova
Tatyana Balakhonova
NDN. M. Danilov
N. M. Danilov
AKA. L. Komarov
A. L. Komarov
EKE. S. Kropachyova
E. S. Kropachyova
IYI. S. Yavelov
I. S. Yavelov
Disclaimer.The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

25 September 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
YKYu. A. Karpov
Yu. A. Karpov
OBOlga Barbarash
Olga Barbarash
ABA. A. Boschenko
A. A. Boschenko
Vasily KashtalapVasily Kashtalap
Vasily Kashtalap
VKV. V. Kukharchuk
V. V. Kukharchuk
ASA. A. Shiryaev
A. A. Shiryaev
Disclaimer The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.Members of the Working Group confirmed the lack of financial support / conflict of interest. In the event of a conflict of interest being reported, the member (s) of the Working Group was (were) excluded from the discussion of sections related to the area of conflict of interest.

6 February 2020 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
EPElizaveta Panchenko
Elizaveta Panchenko
EKEkaterina Kropacheva
Ekaterina Kropacheva
ADAnatoly Dobrovolsky
Anatoly Dobrovolsky
ETElena Titaeva
Elena Titaeva
OZOksana Zemlyanskaya
Oksana Zemlyanskaya
AGAlevtina Grontkovskaya
Alevtina Grontkovskaya

25 November 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
AKA. L. Komarov
A. L. Komarov
EPElizaveta Panchenko
Elizaveta Panchenko
ISI. I. Staroverov
I. I. Staroverov
RSR. M. Shahnovich
R. M. Shahnovich
IYI. S. Yavelov
I. S. Yavelov
The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

28 October 2021 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
ICIrina E. Chazova
Irina E. Chazova
SGSergei P. Golitsyn
Sergei P. Golitsyn
JZJuliya V. Zhernakova
Juliya V. Zhernakova
EZEkaterina A. Zheleznova
Ekaterina A. Zheleznova
EKEkaterina S. Kropacheva
Ekaterina S. Kropacheva
ЮАЮричева Юлия Александровна
Юричева Юлия Александровна
Arterial hypertension (AH) is a leading risk factor for cardiovascular disease as well as it is the most common, independent and potentially reversible risk factor for atrial fibrillation (AF). AH contributes to the occurrence and maintenance of AF due to hemodynamic disorders, alterations in cardiomyocyte electrophysiological properties and structural remodeling in the atria. AF, which is also associated with an increased risk of cardiovascular events, is the most common arrhythmia. AH and AF often coexist, and their prevalence increases with age. This consensus provides the key features of the management of patients with these nosological units. The pathogenesis, risk stratification, and features of the selection of antihypertensive, antiarrhythmic and antithrombotic therapy are described in detail.

1 March 1997 in Angiology
Verified
Journal Article
Closed access
AEA. Eshkeeva
A. Eshkeeva
ADA. Dobrovolsky
A. Dobrovolsky
ETE. Titaeva
E. Titaeva
YPYa. Podinovskaya
Ya. Podinovskaya
KHK.M.A. Hussain
K.M.A. Hussain
EPElizaveta Panchenko
Elizaveta Panchenko
Seventy-one patients with peripheral arterial occlusive disease (PAOD) were random ized into two groups of different treatment modalities. The diagnosis of PAOD was estab lished by history of intermittent claudication, clinical examination, and by Doppler pressure assessment or lower extremity arteriography. After a three-month washout period, 35 patients (Group 1) started treatment with indobufen (400 mg per day) and 36 patients (Group 2) with pentoxifylline (600 mg per day). Twenty-nine patients from each group completed six months of treatment. Both of the drugs significantly improved maximal and pain-free walking distances, but the effect of indobufen was more pronounced than that of pentoxifylline. Patients with PAOD exhibited signs of hyperco agulation. Fibrinogen, D-dimer, and b-thromboglobulin concentrations did not change significantly following treatment in both of the groups. The authors observed a decrease of platelet aggregation after treatment with indobufen and a decrease of F1+2 fragment and PAI-1 antigen after treatment with pentoxifylline.